Founded in 1995, SOSV is a global venture capital firm headquartered in New Jersey. It focuses on seed-to-growth stage investments in deep tech innovations, primarily in bio-tech/life sciences and hardware/robotics sectors, with a commitment to human and planetary health.

Alexandria Venture Investments is the strategic venture capital arm of Alexandria Real Estate Equities. Based in Pasadena, California, it provides long-term strategic capital to innovative life sciences and technology companies developing breakthrough therapies, diagnostics, and platforms across biopharma, digital health, agrifoodtech, agtech, and related healthcare fields. Established in 1996, the firm invests across seed, early, and growth stages and leverages its deep industry knowledge, extensive investor networks, and scientific advisory resources to support portfolio companies. The unit also pursues opportunities at the intersection of real estate, life sciences, and technology, reflecting its parent company's sector focus and integrated ecosystem approach. It aims to help entities advance human health by partnering with founders to scale transformative technologies.

Founded in 1986, ARCH Venture Partners is a venture capital firm specializing in investments that bring innovations in life sciences to market. It focuses on companies co-founded by scientists and entrepreneurs, with a strong track record in commercializing technologies from academic research institutions and national laboratories.

Founded in 1989, OrbiMed is a New York-based healthcare-dedicated investment firm managing approximately $5 billion in assets. It invests across the spectrum of healthcare companies, from private start-ups to large multinational corporations, focusing on biopharmaceuticals, life sciences, digital health, medical devices, and diagnostics sectors globally.

Eli Lilly and Company is a global pharmaceutical leader engaged in the discovery, development, manufacture, and sale of medicines. It operates facilities in the United States, Puerto Rico, and many other countries, with products sold in about 135 countries. The company focuses on therapies in neuroscience, cardiometabolic, cancer, and immunology, and also conducts research in animal health and animal agriculture. Lilly supports patient outcomes and education through a philanthropic foundation that funds programs in underserved communities, including STEM education in Indianapolis.

Founded in Boston in 2004, RA Capital is an investment firm specializing in life sciences and drug development. Its team, with backgrounds in biology, chemistry, medicine, and industry experience, invests in early-stage companies with promising technologies and products across healthcare and life science sectors.

Founded in Paris in 1972, Sofinnova Partners is a venture capital firm dedicated to life sciences investments. With over €2 billion under management, the firm actively partners with entrepreneurs from seed to later-stage, focusing on biopharmaceuticals, medical devices, and industrial biotechnology. Sofinnova proactively sources deals, often leading Round A financings, and plays an active role in portfolio companies until exit.

Novo Holdings is a Danish holding and investment firm managing the assets of the Novo Nordisk Foundation. Established in 1999, it invests globally in life science companies at all stages of development, with a portfolio also including equities, bonds, real estate, and infrastructure.

Khosla Ventures is a California-based venture capital firm founded in 2004 by Vinod Khosla. It provides capital and strategic guidance to startups across stages, focusing on technology-driven companies in areas such as artificial intelligence, climate and sustainability, enterprise software and services, fintech, digital health, medical technology and diagnostics, therapeutics, consumer products, and frontier technologies. The firm backs bold ventures with the potential to disrupt markets and improve lives, supporting companies from early to growth stages and working closely with entrepreneurs to apply science, technology and innovative business models. While primarily investing in North American technology companies, Khosla Ventures pursues opportunities globally and emphasizes experimentation and impact alongside financial returns. The firm also maintains related impact initiatives that support entrepreneurs addressing socio-economic challenges in emerging markets.

Casdin Capital is a New York‑based investment firm founded in 2012 by Eli Casdin. The firm specializes in fundamental research and long‑short equity strategies focused on the life sciences and healthcare sectors, including oncology, digital health, and agtech. In addition to its public‑market fund, Casdin Capital invests in early‑stage to late‑stage private companies within these industries. It operates as a Registered Investment Adviser and, as of October 2020, managed approximately $2.2 billion in assets.

Founded in 1999, Versant Ventures is a global healthcare investment firm dedicated to supporting exceptional entrepreneurs building innovative companies. With over $2 billion under management and offices across North America and Europe, the firm invests across all stages of healthcare company development, with a focus on novel therapeutics. Versant's team, with deep investment, operating, and scientific expertise, takes a hands-on approach to company building.

Invus Financial Advisors, LLC is an employee-owned investment firm based in New York, founded in 2006. The firm specializes in private equity investments and manages pooled investment vehicles, including hedge funds and funds of funds. Invus focuses on making direct and indirect investments in special situations, venture capital, and growth equity stages, with an emphasis on smaller companies and opportunistic co-investments. The firm adopts a flexible approach, recognizing the uniqueness of each company and the complexities of business transformation. Invus maintains a long-term commitment to its investments, aligning its incentives with those of its partners. With a history of empowering owner-managers since 1985 and a strong backing from a group of European families, Invus Financial Advisors manages over $4 billion in an evergreen fund and operates additional offices in London, Paris, and Hong Kong.

Polaris Partners is a venture capital firm based in Boston, Massachusetts, with offices in San Francisco. Founded in 1996, it targets investments in technology and life science companies across the United States and Europe, supporting startups from early formation to profitable growth. The firm's healthcare and biotechnology focus encompasses digital health, consumer-centric care delivery, patient-provider solutions, data science and analytics, as well as therapeutics, genomics and other life science platforms. It backs companies across business-to-business and business-to-consumer models, software as a service, healthcare information technology and health tech sectors, partnering with repeat entrepreneurs to build durable, scale-ready businesses.

New Enterprise Associates is a venture capital firm founded in 1977 and based in Menlo Park, California, with offices in the United States, India and China. It makes investments across technology and healthcare startups at multiple stages, from seed to growth, including software, cloud, data, internet services, fintech, AI, e-commerce, and enterprise technology, as well as healthcare information technology, life sciences, medical devices, and biopharma. It also considers energy technology and infrastructure opportunities, such as solar, batteries and smart grids. The firm pursues a global approach, with activity in the United States, Asia and other regions, and supports companies through rounds of financing ranging from small to sizable investments as they scale. NEA focuses on building portfolios in software, IT services, consumer technology, and healthcare technology, backing ambitious entrepreneurs across sectors and geographies.

Atlas Venture is an early-stage venture capital firm based in Cambridge, Massachusetts, specializing in life sciences and biotechnology. It supports the translation of high-impact scientific discoveries into medicines for patients through a seed-led venture creation strategy that identifies and builds scalable companies with strong scientific foundations. The firm combines experienced scientists and career venture capitalists to select compelling opportunities and realize value, emphasizing early-stage investments in life sciences and technology. Atlas Venture also maintains a multi-disciplinary team able to advance startups from concept to clinical development and commercial viability.

Founded in 2000, Lux Capital is a venture capital firm based in New York and Silicon Valley. It manages over $5 billion in assets, focusing on seed to growth investments at the intersection of technology and sciences. Lux actively supports entrepreneurs building successful businesses in high-growth sectors such as biochemistry, material science, electronics, infrastructure, aerospace, genomics, synthetic biology, and robotics.

Founded in 1969, F-Prime Capital is a venture capital firm based in Cambridge, Massachusetts. It invests globally in technology and healthcare sectors, supporting entrepreneurs with its extensive domain expertise and relationships.

Qiming Venture Partners is a China-based venture capital firm founded in 2006, with offices in Shanghai, Beijing, Suzhou, Hong Kong and Singapore, and a global arm through Qiming Venture Partners USA. It manages multiple funds and invests in early and growth-stage companies across technology, information technology, healthcare, new consumer sectors, AI, robotics, semiconductors, software and digital health. The firm emphasizes a hands-on approach, often taking board seats and providing operational guidance to help CEOs scale and reach exits. Through its investments, it has backed hundreds of companies and supported numerous IPOs and M&A outcomes, with unicorns among its portfolio, illustrating breadth and depth across China and international markets.

Redmile Group, established in 2007, is a private equity firm headquartered in San Francisco with an additional office in New York. The company specializes in healthcare investments, focusing on venture capital opportunities within the sector.

Established in 2020, the European Innovation Council supports innovative startups and researchers with promising ideas, focusing on early-stage companies with positive environmental, social, or governance impacts. It co-invests alongside private investors.

Kurma Partners is a Paris-based investment firm founded in 2009 that concentrates on financing innovation in healthcare and biotechnology across Europe. It targets early-stage and development capital for companies in life sciences, biotechnology, digital health, and related fields, and emphasizes collaborations with research institutes and hospitals to advance therapies and medical technologies from concept to clinical development. The firm operates as a specialist investor in Europe, supporting ventures that bridge scientific discovery and patient impact through equity investments and strategic guidance.

Deerfield Management is a New York-based investment firm established in 1994 that focuses on healthcare. It operates across investment, information, and philanthropy to support the healthcare ecosystem. The firm provides private and public investments and offers long-term, structured capital to both public and private healthcare companies. Its portfolio spans life sciences, medical devices, diagnostics, digital health, and health services. As an investment adviser, it seeks opportunities in healthcare products and services and aims to accelerate innovation by combining capital with industry insight.

Mission BioCapital is a life science venture capital firm investing in early-stage companies within the biotechnology sector. Founded in Cambridge, Massachusetts in 2009, the company is known for its experienced leadership team and deep support provided to portfolio companies.

Leaps by Bayer is the corporate venture capital arm of Bayer. Established in 2015 and headquartered in Leverkusen, Germany, it invests in life sciences, including healthcare, biotechnology, and agriculture. The firm seeks long-term, disruptive technologies and supports innovations with potential for significant societal impact.

Northpond Ventures is a science-driven venture capital firm based in Bethesda, Maryland, with additional offices in San Francisco, California, and Cambridge, Massachusetts. Founded in 2018, the firm concentrates its investments in life sciences, diagnostics, therapeutics, digital health, and related technologies, including AI and machine learning applications in biotech and medical fields, as well as environmental and other emerging technologies. It seeks to back early- and growth-stage companies that advance biomedical research, diagnostics, medical devices, and technology-enabled health solutions. The firm operates as a registered investment adviser and emphasizes building a better tomorrow through science-driven investing. It focuses on strategy, value creation, and supporting companies at the intersection of life sciences and technology, aiming to accelerate innovations that improve health outcomes.

Sequoia Capital Israel is a venture capital firm that backs startups and growth companies across seed to late-stage rounds, with a focus on Israel. It invests across sectors including fintech, financial services, internet, mobile, technology, and healthcare, spanning banking, payments, advertising, ecommerce, data, security, software, and related enabling tech. Typical commitments range from 100,000 to 1 million in seed, 1 to 10 million in early venture, and 10 to 100 million in growth rounds. The firm is based in Tel Aviv and operates as part of Sequoia Capital's global network.

Forbion is a venture capital firm based in Naarden, Netherlands, established in 2006. It specializes in early-stage investments within the life sciences and MedTech sectors, focusing on companies involved in drug development and addressing critical medical needs. The firm has a team of nine investment professionals and has built a strong track record since the late 1990s, with successful investments in various notable companies. Forbion manages assets exceeding €400 million across three active funds and co-manages BioGeneration Ventures, which targets academic spin-outs and seed investments in the Netherlands. The firm continues to play a significant role in advancing innovative healthcare solutions through its strategic investments.

Andreessen Horowitz is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz and based in Menlo Park, California. It funds startups across the entire lifecycle, from seed to growth, with a broad focus on software and technology-enabled businesses. The firm backs companies in software, cloud infrastructure, digital platforms, data storage, and mobile and Internet services, as well as sectors at the intersection of technology with life sciences, such as bio healthcare and computational medicine. Its investments span artificial intelligence, fintech, consumer and enterprise software, crypto and blockchain, cybersecurity, and related infrastructure. Through strategic guidance and a hands-on approach, the firm aims to help portfolio companies scale and innovate.

Founded in 2011, DCVC is a venture capital firm based in Palo Alto, California. The firm invests in early-stage companies utilizing deep tech to solve complex problems across sectors such as artificial intelligence, exascale computing, climate, engineering, materials science, robotics, space, water, biology, defense, and security.

Venrock is a Palo Alto-based venture capital firm founded in 1969 as the venture capital arm of the Rockefeller family. It concentrates on seed and early-stage investments in technology and healthcare, with interests spanning information technology, life sciences and related sectors in the United States. The firm has supported a broad portfolio of companies, including Apple, Intel, Illumina, DoubleClick, Athenahealth, Gilead Sciences, Nest, SlideShare and Tudou. Venrock emphasizes long-term partnerships with entrepreneurs, combining hands-on venture support with rigorous data analysis to help startups grow into enduring companies.

Founded by Bill Maris in 2017, Section 32 is a California-based venture capital firm focused on early-stage investments across life science, healthcare, and technology sectors. The company aims to accelerate the discovery and development of revolutionary technologies that improve human conditions.

BioVenture, established in September 2013, specializes in early-stage venture capital investments in the field of life sciences, focusing on biotechnology, drug discovery, medical devices, and healthcare services companies. With a fund size of 540 million yuan, BioVenture provides capital and post-investment support to innovative companies with high growth potential. Backed by Suzhou Industrial Park and BioBay, BioVenture aims to become one of China's most successful medical and pharmaceutical venture funds by leveraging its industry expertise and resources. The team at BioVenture consists of senior investment professionals with deep knowledge of domestic and foreign markets, aiming to help companies grow rapidly and achieve greater success while delivering considerable returns to fund investors. Through joint venture development cooperation, BioVenture seeks to drive innovation and growth in the medical and pharmaceutical industry.

EcoR1 Capital is a San Francisco-based investment firm focused on biotechnology. It provides advisory and investment services to biotechnology companies, pursuing venture-style opportunities in both private and public markets and supporting therapies with potential patient impact. Founded in 2012, the firm emphasizes scientific innovation and translational research and draws inspiration from the EcoR1 restriction enzyme. As an investment adviser, EcoR1 Capital collaborates with clients and partners in the biotech sector to identify promising treatments and help companies address unmet medical needs.

SR One is the corporate venture capital arm of GlaxoSmithKline, investing globally in early-stage life science companies pursuing innovative science with the potential to significantly improve medical care. Since 1985, SR One has invested about $800 million in more than 180 companies.

The Column Group is a San Francisco-based venture capital firm focused on biotechnology and life sciences, with emphasis on drug discovery and development. It backs early-stage and seed companies in the United States, aiming to build science-driven businesses capable of delivering multiple product opportunities rather than short-term exits. The firm concentrates on oncology and other disease areas including inflammation, infectious disease, metabolic and cardiovascular disorders, and nervous system conditions, seeking to support platform-based discoveries with potential for significant therapeutic impact.

Founded in 2016, Illumina Ventures is an independently managed venture capital firm based in Foster City, California. It invests primarily in early-stage companies focused on genomics-enabled innovations across life science research, healthcare, agriculture, and environmental science sectors. The firm leverages its strategic partnership with Illumina, a leading genomics solutions provider, for added value and expertise.

Founded in 2016, Digitalis Ventures is a New York-based venture capital firm focusing on early-stage investments in health technologies & services, life sciences, and animal health sectors. The firm partners with entrepreneurs across all stages of venture investing, spanning the full continuum of the healthcare ecosystem.

Alumni Ventures Group is a venture capital firm based in Manchester, New Hampshire, with offices across North America. It provides access to venture investing for individual accredited investors, particularly alumni networks, by offering diversified portfolios of venture opportunities and allowing members to invest alongside fellow alumni in ventures led by peers. The firm backs early-stage and later-stage opportunities across technology, consumer, healthcare, financial services, and other sectors, with a sector- and geography-agnostic approach. It typically invests between $10,000 and $3 million per deal and emphasizes the involvement of alumni connections and an institutional lead investor in opportunities. Alumni Ventures also offers focused funds to broaden participation, enabling accredited investors to access venture portfolios diversified by type, sector, stage, and geography. The model aims to democratize access to venture capital while maintaining rigorous selection standards through alumni networks.

Founders Fund is a San Francisco-based venture capital firm that backs science and technology companies across multiple stages, from seed to late-stage. It pursues transformative technologies and follows a founder-friendly investment approach that provides substantial support with minimal interference. The firm invests in ventures solving difficult problems across sectors such as aerospace and transportation, artificial intelligence, advanced computing, energy, healthcare, biotechnology, cybersecurity, fintech, consumer internet, software, robotics, and related technology fields. It has backed notable companies early, including SpaceX, Palantir, and Facebook, reflecting a history of partnering with ambitious founders to scale breakthrough technologies.

Osage University Partners is a venture capital firm focused on investing in startups commercializing university technologies. It partners with research universities to invest in their university spinouts, sharing investment profits with partner institutions. The firm funds software, hardware, and life sciences companies at all stages of development. It has partnered with over 80 universities, including 36 of the top 50 U.S. institutions by research expenditures, and has invested in over 50 university spinouts.

Founded in 2000, Partners Investment is a venture capital firm based in Seoul, South Korea. It focuses on investing in various sectors including software, biotechnology, healthcare services, semiconductors, and telecommunications.

Flagship Pioneering is a Cambridge, Massachusetts-based venture creation firm that conceives, creates, resources, and grows first-in-category companies across health technology, biotechnology, medicine, engineering, energy, and related fields. The organization aims to transform human health and sustainability by turning seemingly unreasonable ideas into transformational ventures through an evolutionary, science-driven approach. It combines inventive capacity, entrepreneurial leadership, and capital management within a single enterprise to systematically build new companies that pursue breakthrough advances in biology, engineering, and medicine. Since its founding in 2000, Flagship Pioneering has developed and nurtured a portfolio of ventures by integrating scientific discovery with disciplined entrepreneurship, seeking to accelerate innovations from concept to market.

Founded in 1849, Pfizer is a global pharmaceutical company dedicated to discovering and developing safe, effective, and affordable medicines. With a broad portfolio across various therapeutic areas, Pfizer focuses on wellness, prevention, treatment, and cures for diseases, including investments in emerging technologies to shape the future of healthcare.

Sofinnova Investments is a venture capital firm founded in 1976 and based in Menlo Park, California, with additional offices in La Jolla, California; Montreal, Quebec; and Tokyo, Japan. It backs early to later-stage startups in life sciences and information technology across the United States and Europe, focusing on West Coast U.S. and developed European markets. In life sciences, the firm pursues clinical-stage pharmaceutical, biotechnology and medical technology companies, including drug discovery platforms and entities addressing diseases with unmet medical needs, covering therapeutic areas such as oncology, respiratory, dermatology, ophthalmology, neurology and women's health. In information technology, it funds product-oriented software, enterprise software, service-provider software, and telecommunications infrastructure. Seed investments in both domains typically range from 0.1 million to 1 million, with initial rounds for technology commonly 3-5 million and life science rounds 5-15 million; total commitments generally span 5-15 million for tech and 15-30 million for life sciences. The firm seeks board seats when leading or co-leading early-stage investments.

Samsara BioCapital is a venture capital firm based in Palo Alto, California, that focuses on biotechnology and life sciences companies in the United States. The firm seeks to invest in pharmaceutical and biotechnology ventures, including oncology and other healthcare technologies, with a goal of supporting entrepreneurs in turning ideas into developed therapies. It emphasizes collaboration with ambitious partners and aims to advance biotech innovation and important new therapies by providing capital and advisory support. The organization also operates as a registered investment adviser, offering investment advisory services to guide portfolio companies through growth and development.

Founded in 1972, Kleiner Perkins is a venture capital firm based in Menlo Park, California. It specializes in investing in early-stage, growth, and incubation companies across various sectors including technology, healthcare, life sciences, and consumer goods. The firm partners with founders from inception to IPO, supporting them to maximize the potential of their ideas.

Founded in 2017, Civilization Ventures is a venture capital firm based in San Francisco. It invests in visionary founders leading the future of health tech and biology-driven innovation, focusing on digital health, synthetic biology, diagnostics, 3D bio-printing, and AI-enabled health tech.

Westlake Village BioPartners is a venture capital firm established in 2018 and based in Los Angeles, California. The firm specializes in incubating and developing early-stage life sciences companies, with a particular emphasis on biotech and pharmaceutical sectors. It partners with entrepreneurs to cultivate transformative therapies and technologies aimed at improving patient outcomes. The firm's approach leverages the founding team's extensive experience in identifying, developing, and commercializing breakthrough medical innovations. By providing initial seed funding, Westlake Village BioPartners supports the early stages of technology development before engaging in more substantial financing rounds.

Founded in 2001 and based in Zug, Switzerland, HBM Healthcare Investments is a venture capital firm focusing on the healthcare sector. It invests globally in mature emerging companies primarily in biotechnology/human medicine, diagnostics, and medical technology sectors.

Established in 1986, Korea Investment Partners is a prominent venture capital firm headquartered in Seoul. With over three decades of experience, the company invests globally in innovative startups across various sectors, including technology, healthcare, and manufacturing. Notable investments include Kakao, Naver, YG Entertainment, and Didi Chuxing. The firm manages multiple funds with total assets under management exceeding US$1.8 billion.